DKBmed Podcasts – Medical Education Podcasts
Volume 4, Issue 8, Part 3.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study, presented at the April 2016 EASL meeting.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS
Volume 4, Issue 8, Part 2.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sofosbuvir-Containing Regimens in Patients Infected with Chronic HCV Who Have Advanced Liver Disease or are Post Liver Transplant(SOLAR-1 & 2 Studies), presented at the April 2016 EASL meeting.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS
Volume 4, Issue 8, Part 1.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals presented at the April 2016 EASL meeting.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS
Volume 3, Issue 12.
Mark S. Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins University School of Medicine, Raymond T. Chung, Associate Professor of Medicine, Harvard Medical School, Director of Hepatology, Vice Chief of Gastroenterology at Massachusetts General Hospital, and Laurent Castera, MD, PhD, Department of Hepatology, Beaujon Hospital, AP-AP, INSERM U773 at the University of Paris-Diderot. Discuss new information presented at the 2014 European Association for the Study of the Liver (EASL) meeting, as well as non-invasive markers of liver disease.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS
Volume 3, Issue 2.
Dr. Mark Sulkowski from The Johns Hopkins University School of Medicine discusses advancements in hepatitis C therapy presented at EASL, as well as case-study scenarios for the clinical practice.
Podcast (eviralhepatitis): Play in new window | Download
Subscribe: Apple Podcasts | Android | RSS